Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from RaQualia Pharma Inc. ( (JP:4579) ).
RaQualia Pharma reported a sharp turnaround to profitability for the fiscal year ended December 31, 2025, with net sales rising 28.1% to ¥3.98 billion and profit attributable to owners of parent reaching ¥273 million, compared with a loss a year earlier. The company’s operating margin improved to 12.2%, equity ratio climbed to 65.1%, and cash and cash equivalents increased slightly to ¥3.24 billion despite negative operating cash flow.
Management has maintained a no-dividend policy for 2025 and continues to forecast zero dividends for 2026, underscoring a focus on reinvestment and capital preservation. For 2026, RaQualia expects flat sales of about ¥3.98 billion but a steep drop in earnings, guiding to an ordinary profit of ¥86 million and a net loss of ¥63 million, which signals anticipated higher costs or investment that may pressure short-term profitability while potentially supporting longer-term growth.
The most recent analyst rating on (JP:4579) stock is a Hold with a Yen1162.00 price target. To see the full list of analyst forecasts on RaQualia Pharma Inc. stock, see the JP:4579 Stock Forecast page.
More about RaQualia Pharma Inc.
RaQualia Pharma Inc. is a Japan-based biopharmaceutical company listed on the Tokyo Stock Exchange that focuses on drug discovery and development. The company generates revenue primarily through licensing and collaborative research related to its pipeline of pharmaceutical candidates, targeting both domestic and international markets in need of innovative therapeutics.
Average Trading Volume: 1,510,367
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen25.12B
See more insights into 4579 stock on TipRanks’ Stock Analysis page.